- Home
- TWO vs AUTL Comparison
TWO vs AUTL Comparison
Compare TWO & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWO
- AUTL
- Stock Information
- Founded
- TWO 2009
- AUTL 2014
- Country
- TWO United States
- AUTL United Kingdom
- Employees
- TWO N/A
- AUTL N/A
- Industry
- TWO Real Estate Investment Trusts
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TWO Real Estate
- AUTL Health Care
- Exchange
- TWO Nasdaq
- AUTL Nasdaq
- Market Cap
- TWO 1.3B
- AUTL 1.1B
- IPO Year
- TWO 2009
- AUTL 2018
- Fundamental
- Price
- TWO $11.62
- AUTL $3.08
- Analyst Decision
- TWO Buy
- AUTL Strong Buy
- Analyst Count
- TWO 8
- AUTL 2
- Target Price
- TWO $14.32
- AUTL $11.50
- AVG Volume (30 Days)
- TWO 1.4M
- AUTL 2.3M
- Earning Date
- TWO 10-28-2024
- AUTL 11-12-2024
- Dividend Yield
- TWO 15.50%
- AUTL N/A
- EPS Growth
- TWO N/A
- AUTL N/A
- EPS
- TWO N/A
- AUTL N/A
- Revenue
- TWO $119,476,000.00
- AUTL $10,091,000.00
- Revenue This Year
- TWO N/A
- AUTL $816.67
- Revenue Next Year
- TWO N/A
- AUTL $374.47
- P/E Ratio
- TWO N/A
- AUTL N/A
- Revenue Growth
- TWO N/A
- AUTL 82.71
- 52 Week Low
- TWO $11.28
- AUTL $2.94
- 52 Week High
- TWO $14.59
- AUTL $7.45
- Technical
- Relative Strength Index (RSI)
- TWO 33.87
- AUTL 35.72
- Support Level
- TWO $11.59
- AUTL $3.24
- Resistance Level
- TWO $11.77
- AUTL $4.12
- Average True Range (ATR)
- TWO 0.30
- AUTL 0.37
- MACD
- TWO 0.02
- AUTL -0.09
- Stochastic Oscillator
- TWO 23.45
- AUTL 8.48
About TWO Two Harbors Investment Corp
Two Harbors Investment Corp is a real estate investment trust primarily focused on investing in, financing, and managing residential mortgage-backed securities, or RMBS; residential mortgage loans; mortgage servicing rights; and commercial real estate. The majority of the company's investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. Two Harbors derives nearly all of its revenue in the form of interest income collected from its investments. Most of this income is generated by available-for-sale securities, while residential mortgage loans held for investment in securitization trusts also contribute a sizable amount.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.